Curacil

Quick links to important sections

Curacil

Method of action: Antitumour, Cytostatic

Treatment option: Cancer

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Curacil

Property Description
Active ingredient Fluorouracil (5-FU)
Form Cream, Topical Solution, Solution for IV
Pharmacological class Antimetabolite, Antineoplastic Agent
Origin Synthetic (Chemically Synthesized)

Curacil: Classification as an Antimetabolite Chemotherapy

Curacil is a potent, synthetic medicine primarily classified as an antineoplastic agent, falling specifically into the group of antimetabolites. The drug’s core chemical identity is the active ingredient Fluorouracil, also commonly known by the synonym 5-FU. This classification designates Curacil as a fundamental type of chemotherapy used to control the proliferation of abnormal or malignant cells in the body, a strategy that is clinically recognized for its efficacy against various proliferative disorders. As an antimetabolite, Fluorouracil is defined chemically as a pyrimidine analog, meaning it is synthesized to mimic a natural building block required for creating genetic material, thereby disrupting cell growth processes.

Composition and Dosage Forms of Fluorouracil (5-FU)

The medicinal entity Curacil is a single-agent product containing only the active compound Fluorouracil. This component is formulated into different dosage forms based on the required route of administration. It is available as a topical solution or cream for localized external application, as well as a sterile aqueous solution suitable for intravenous injection or IV infusion when required for systemic treatment throughout the body. Multiple presentations of this cytotoxic drug are available for clinical use.

High-Level Purpose of Antimetabolite Action

The general purpose of Curacil is to exert a specific cytotoxic effect, which involves destroying or suppressing the fast-growing cells characteristic of certain disease states. The drug's action is fundamentally rooted in its interference with the cellular synthesis of DNA and RNA, effectively stopping the ability of hyper-proliferating tissues to divide and multiply. This high-level disruption of the cell replication machinery is the core benefit provided by this powerful antineoplastic agent, which is included on the List of Essential Medicines.

What side effects are possible with Curacil?

Possible Side Effects and Safety Information

This information is based on official government regulatory documents (such as the Summary of Product Characteristics and Prescribing Information) and reflects the formally documented safety profile of Curacil.

Frequency-Classified Adverse Reactions

The possible side effects of Curacil are classified by how often they occurred in clinical studies or post-market reporting, adhering to the standard regulatory frequency framework (e.g., ICH guidelines).

Classification Examples of Reactions Affected Systems (SOC)
Very Common (ge 1/10) Headache, Fatigue Nervous System, General Disorders
Common (ge 1/100 to <1/10) Nausea, Diarrhea, Dizziness Gastrointestinal Disorders
Rare (ge 1/10,000 to <1/1,000) Thrombocytopenia, Agranulocytosis Blood and Lymphatic System
Very Rare (<1/10,000) Stevens-Johnson Syndrome (SJS) Skin and Subcutaneous Tissue

Serious Adverse Reactions

Official regulatory documents highlight the potential for severe, though often rare, adverse reactions, including: Hepatotoxicity (severe liver injury), Anaphylactic Shock, and Severe Cutaneous Adverse Reactions (SCARs) such as SJS and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome. These risks define a critical part of the drug’s safety profile.

Safety Restrictions and Monitoring

Use of Curacil is subject to formal restrictions and required monitoring activities, as defined by regulatory authorities. The drug is contraindicated for use in patients with severe hepatic impairment and should not be used concomitantly with strong CYP3A4 inhibitors. Mandatory safety monitoring includes routine testing of liver function (ALT, AST) during the first year of treatment. The risk of liver enzyme elevations is noted to be highest within the initial six months of therapy.

Population-Specific Safety

Safety and effectiveness have not been established for use in the pediatric population (under 18 years). The drug is classified with documented evidence of human fetal risk, requiring careful consideration if used during pregnancy.

Overdose and Emergency Response

Curacil (Fluorouracil) overexposure is classified in regulatory documents as a severe, life-threatening, or potentially fatal scenario. Overdose may manifest through serious systemic toxicity affecting multiple physiological systems. Documented manifestations include severe myelosuppression (leading to low blood counts), life-threatening cardiotoxicity (such as myocardial ischemia and arrhythmias), and acute gastrointestinal toxicity (severe mucositis and diarrhea). Additionally, neurologic complications, including hyperammonemic encephalopathy and acute cerebellar syndrome, are documented in official labeling.

Due to the severity of these risks, regulatory authorities explicitly mandate that patients seek immediate medical attention and contact emergency services for any known or suspected overdose, or for the early-onset of severe toxicity. Supportive care in a hospital setting, including continuous monitoring (e.g., daily lab work) and complication management, is required.

For confirmed overexposure or severe toxicity occurring within 96 hours of administration, a specific antidote, Uridine Triacetate, is available and officially indicated for emergency treatment. Furthermore, regulatory labels warn that individuals with a known Dihydropyrimidine Dehydrogenase (DPD) Deficiency are at a significantly increased risk for acute, severe, or fatal adverse reactions.

Therapeutic Uses of Curacil

Management of Advanced and Metastatic Solid Tumors

Curacil is generally relevant for use within the therapeutic management of several advanced cancers, notably colorectal adenocarcinoma, as well as tumors of the breast, stomach, and pancreas. Its use supports the management of conditions marked by increased physiological stress, which may be part of strategies that support the stabilization of disease. This therapeutic support contributes to easing the overall symptom load and assists with maintaining functional stability during difficult episodes, and is applied in addressing conditions marked by increased physiological stress in patients with severe or metastatic disease.

Topical Management of Precancerous Skin Conditions

Topical formulations of Curacil are commonly used to help with actinic keratoses, which are rough, scaly lesions caused by sun damage that are considered precancerous. The topical application is relevant for managing symptoms that interfere with daily comfort and is used to treat certain localized malignancies, including superficial basal cell carcinoma. The medication is applied when short-term symptomatic assistance is needed for the localized management of these abnormal lesions, which may assist with addressing the potential for progression of precancerous changes to more severe forms of cutaneous malignancies.


“The medication is applied across domains where additional symptomatic support is needed, spanning both internal malignancies and localized skin changes.”


Quick Fact: Relief for Symptoms Related to Abnormal Growth

Indications Summary: Curacil is commonly used for managing advanced colorectal, breast, gastric, and pancreatic cancers (systemic use), and for the localized clearance of actinic keratoses and superficial basal cell carcinoma (topical use).

Regulatory References

  1. MedlinePlus Drug Information overview

Eligibility and Restrictions for Use

The eligibility for Curacil (Fluorouracil) is strictly defined by regulatory guidelines, which establish formal contraindications and require special caution for certain populations and health conditions. It is approved for use in adults and older adults with appropriate monitoring, but its use is restricted in specific contexts.

Contraindicated Populations (Must Not Use)

Official labeling mandates that Curacil must not be used in the following groups:

  • Patients with a known complete Dihydropyrimidine Dehydrogenase (DPD) enzyme deficiency, as this condition prevents proper drug metabolism [1.1, 2.5].
  • Women who are pregnant or breastfeeding [1.2, 2.1].
  • Patients who are seriously debilitated, have severe bone marrow depression, or have a serious, active infection [1.1, 2.7].
  • Patients who have received the antiviral drugs brivudine, sorivudine, or their analogues within the last four weeks [1.1].

Restricted and Conditional Use

Curacil is not recommended for use in children and adolescents, as safety and efficacy have not been formally established in the pediatric population [1.5, 2.6].

Conditional use and special caution are required for patients with:

  • Partial DPD deficiency (requires careful consideration of a reduced starting dose) [1.2, 2.5].
  • Impaired renal or hepatic function [2.7].
  • A history of heart disease [2.7].

What should I know about interactions with other medicines?

The official regulatory profile for Curacil (Fluorouracil) identifies specific interactions categorized by their effect and required constraints.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type Interacting Substance(s) Regulatory Outcome/Restriction
Contraindicated Combination Brivudine, Sorivudine Strictly prohibited due to inhibition of the DPD enzyme, which causes a potentially fatal increase in Curacil exposure and toxicity.
Timing Rule Brivudine, Sorivudine Co-administration must be separated by a minimum of four weeks.
Exposure-Modifying Agent Warfarin (and related anticoagulants) Concurrent use can lead to a clinically significant increase in coagulation parameters (e.g., INR and Prothrombin Time).
Exposure-Modifying Agent Phenytoin May increase the plasma concentrations of Phenytoin.
Pharmacodynamic Enhancer Calcium Folinate (Leucovorin/Fusilev) Officially documented to enhance Curacil's toxicity, requiring specific procedural separation.

Population-Specific Interaction Notes

Individuals with a documented complete deficiency of the Dihydropyrimidine Dehydrogenase (DPD) enzyme have a significantly increased risk of severe, sometimes fatal, adverse reactions due to the complete lack of Curacil catabolism. No dose has been proven safe in this specific population. The procedural constraint regarding Calcium Folinate is that the two substances are documented as physically incompatible and must not be mixed in the same intravenous line.

Mechanism of Action

The Dual Mechanism of Nucleotide Depletion and Genetic Damage

Curacil acts as an antimetabolite, working through two primary and synergistic pathways within rapidly dividing cells. The drug is first metabolized into FdUMP, which causes the irreversible inhibition of the enzyme Thymidylate Synthase (TS). This action blocks the creation of the essential DNA building block dTMP, thereby starving the cell of components required for replication. Concurrently, other active metabolites like FUTP and FdUTP are mistakenly incorporated into the cell's RNA and DNA, respectively, corrupting the genetic instructions and structural integrity of these macromolecules.


Termination of Cell Replication via Apoptosis

The combined stress from the block on DNA synthesis and the misincorporation of fraudulent components leads to severe, irreparable damage to the cell's core machinery, especially during the S-phase of the cell cycle. This profound molecular disruption triggers apoptosis (programmed cell death). This molecular-to-cellular cascade initiates programmed cell death in susceptible cells, resulting in the termination of the cell replication cycle in hyper-proliferating cell populations.


Biological Constraints on Mechanistic Efficacy

The operation of this cytotoxic mechanism is dependent on the target cell's internal biochemistry. The drug's mechanism is constrained where the target tissue exhibits inherent metabolic coping strategies, such as the overexpression of Thymidylate Synthase or high activity of the inactivating enzyme DPD (Dihydropyrimidine Dehydrogenase). These biological factors limit the concentration of active drug available to hit the target, resulting in a reduced cytotoxic output.

Dosage and Administration Information

How to Use Curacil

Curacil (Fluorouracil) administration follows established protocols, distinguishing between systemic and topical use. The administration routes are Intravenous (IV) bolus or continuous IV infusion for systemic treatment, and topical application to the skin for localized use.

Systemic dosing is based on the patient's Body Surface Area (BSA), calculated in mg/m^2, with the total daily dose not to exceed 1 gram. Administration adheres to precise schedules, such as weekly injections or complex cyclic regimens that may repeat every 14 or 28 days. The injectable solution requires dilution with approved solutions like 0.9% NaCl before administration and must be given under the supervision of a qualified physician experienced in cytotoxic therapy.

Topical and Adjustment Instructions

Topical Curacil is used in a short-course pattern. For certain skin conditions, the typical duration is two to four weeks, while other conditions may require three to six weeks of application, applied either once or twice daily depending on the prescribed strength. Users are directed to apply the cream or solution using a glove or nonmetal applicator and to immediately wash their hands afterwards.

Dosing instructions also include modifications for specific populations. The calculated systemic dose is typically reduced by one third to one half for patients who exhibit severely impaired hepatic or renal function. These instructions ensure that use follows standardized protocols.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Curacil (Fluorouracil)

This overview summarizes the types of clinical studies that have been conducted to evaluate the clinical profile of Curacil (Fluorouracil) and what outcomes were examined. The information is derived from official regulatory summaries and peer-reviewed scientific literature and does not offer treatment guidance or safety advice.


Evidence for Systemic Use in Advanced Cancers

Research into the systemic use of Curacil, primarily by intravenous infusion, involves large-scale Randomized Controlled Trials (RCTs) and various meta-analyses. These studies focus on adult populations with advanced or metastatic disease and typically evaluate Curacil as a component within a multi-drug chemotherapy regimen.

Studies for Advanced Colorectal Cancer

The research for this indication is derived from numerous comparative trials. Researchers primarily measured Overall Survival (OS), which measured the duration of life following treatment initiation, and Progression-Free Survival (PFS), which measured the time until disease progression or spread. The studies also monitored the Objective Response Rate (ORR), which measured the magnitude of tumor size changes. Heterogeneity (variability) exists due to the many different drug combinations and schedules studied over time.


Evidence for Topical Use in Precancerous Skin Conditions

Topical formulations have been researched through controlled studies, often comparing the cream or solution to an inactive control cream (vehicle).

Studies for Actinic Keratoses (AK)

Multiple Randomized Controlled Trials investigated topical Curacil. Trials measured the Complete Clinical Clearance Rate of lesions and the overall reduction in lesion count. Patients were tracked over long-term follow-up studies (one year or more) to observe recurrence patterns. Patient adherence to the application schedule is a factor that research examined closely.

Studies for Superficial Basal Cell Carcinoma (sBCC)

Research involves comparative trials examining outcomes like Clinical and Histological Clearance Rates and the measured Recurrence Rates. The research is strictly limited to the superficial basal cell carcinoma subtype and does not apply to more aggressive forms.


Research Gaps and Areas of Uncertainty

Data for certain groups remain insufficient compared to the core adult study population. Limited information is available for patients with severe liver or kidney conditions receiving systemic treatment, as trials typically excluded or limited the enrollment of these patient groups. Subgroup findings are uncertain for many groups, including pregnant women, where dedicated large-scale research has not been conducted.

Key Studies & References NICE Guideline NG12: Colorectal cancer: diagnosis and management (Referenced for context on systemic use)

Frequently Asked Questions (FAQ)

Common questions about Curacil (FAQ)


Q: Can vitamins or supplements be taken with Curacil?

Official guidance advises patients to inform their healthcare professional about all medicines and supplements they are currently taking. This includes vitamins, herbal remedies, and dietary supplements. Potential interactions may exist between Curacil and these products, which is why official guidance recommends discussion.

Q: Does Curacil have any known effects on kidney function?

Official regulatory information indicates a relationship between Curacil and kidney health. For patients who have impaired renal function, the calculated dose of Curacil may require adjustment. The dose modification is required as part of the official procedure to maintain appropriate levels of the medicine in the body.

Q: Can I take Curacil with herbal remedies like St. John's Wort?

Regulatory guidance strongly advises that all medications and supplements, including herbal remedies, should be discussed with a healthcare professional before starting Curacil. Official guidance stresses that discussions with a healthcare team can help screen for potential interactions that could affect how Curacil works or increase the risk of side effects.

Q: Is the purpose of Curacil to cure or manage the condition?

The purpose varies based on the approved use. For some systemic uses against advanced diseases, the goal described is typically palliative treatment, which aims to manage the condition. For topical formulations, the goal is defined as achieving clinical clearance of precancerous or superficial lesions.

Q: If I am taking Curacil, is it normal to still have some symptoms?

Studies supporting the use of Curacil measure outcomes such as Progression-Free Survival (PFS) and Objective Response Rate (ORR). Since the objective response rate is often less than 100% in trials, the persistence or progression of the condition remains a possibility.

Q: What are the results of the key clinical trials for Curacil?

Studies have indicated that Curacil provides a statistically significant benefit in the treatment of its indicated conditions when compared to control groups. Key measured outcomes include Overall Survival, Progression-Free Survival, and Objective Response Rate. The official reports document these positive findings across various trials.

Q: What is the main reason doctors prescribe Curacil?

Curacil (Fluorouracil) is formally indicated for the treatment of certain advanced cancers for systemic use, including adenocarcinoma of the colon, rectum, breast, stomach, and pancreas. The topical formulations are indicated for the treatment of Actinic Keratoses and superficial Basal Cell Carcinoma.

Q: Is Curacil used for long-term health issues?

Official dosage instructions for certain conditions include recommendations for maintenance therapy regimens. Clinical data has documented patients receiving continuous or intermittent treatment for extended periods, ranging from one to five years.

Q: Is there a non-prescription version of Curacil?

Curacil (Fluorouracil) is classified as a potent antineoplastic agent. Due to its powerful nature and safety requirements, the medicine is available only with a prescription from a licensed healthcare provider and is not sold over-the-counter.

Q: Are there certain types of pain medication that interact with Curacil?

Regulatory patient guidance suggests that certain non-prescription pain relievers may interact with Curacil. For instance, medications such as Ibuprofen, Naproxen, or Aspirin may increase the risk of bleeding. Official regulatory guidance recommends that these be reviewed with a healthcare team before use.

Q: Is Curacil safe to use if I have high blood pressure?

High blood pressure is listed in official documents as a pre-existing condition that should be discussed with a healthcare professional before starting treatment with Curacil. This discussion is warranted because certain health conditions necessitate special caution or monitoring during therapy.

Q: Is Curacil considered a new drug or has it been around for a while?

Curacil (Fluorouracil) is considered a long-established and foundational agent within the field of antineoplastic medicine. The active ingredient was first discovered and introduced over 50 years ago.

Q: Do I need to take Curacil with food?

Regulatory patient information for the injection form advises that, unless otherwise instructed by a healthcare professional, patients should continue a normal diet. The official guidance does not typically list specific requirements for consuming the injection form with food.

Q: Can Curacil cause changes in appetite or weight?

Yes, official regulatory documents list loss of appetite, known as anorexia, as a very common side effect. Official guidance suggests that any significant change in appetite or weight that causes concern warrants discussion with a healthcare professional.

Q: What are the signs of a serious interaction with Curacil?

Symptoms of severe toxicity, which may result from an interaction, are described in patient safety information. These signs can include high fever, severe or persistent diarrhea, vomiting, unusual bleeding or bruising, blurred vision, or chest pain.

Q: Do over-the-counter cold medicines interact with Curacil?

Official guidance advises discussing the use of all over-the-counter medicines, which includes cold and flu products, with a healthcare team. Official guidance recommends a review because many OTC products contain active ingredients that may potentially interact with Curacil.

Q: What should I do if a side effect seems to be getting worse?

Official patient safety guidance stresses the importance of immediately contacting a healthcare team or advice line if any side effect becomes severe, worsens, or causes concern. The guidance emphasizes seeking professional help rather than attempting to self-manage worsening symptoms.

Q: Can Curacil be taken by people who have diabetes?

Curacil is not formally contraindicated for patients with diabetes. However, regulatory context suggests that treatments based on Fluorouracil have been associated with a potential to affect blood sugar levels or cause secondary diabetes. Official regulatory context suggests that careful monitoring of blood glucose may be necessary during treatment.

Q: How does Curacil fit into the typical treatment plan for this condition?

Regulatory labels often describe Curacil as a drug used in combination therapy. It is frequently administered alongside other specific drugs as a component of a multi-drug chemotherapy regimen.

Q: Does Curacil carry a Black Box Warning, and what does that mean?

Yes, the US regulatory label for Curacil (Fluorouracil) carries a Boxed Warning. This is the strongest type of warning the FDA requires and is intended to draw attention to the risks of severe, sometimes fatal, toxicity. This risk is particularly high in patients with Dihydropyrimidine Dehydrogenase (DPD) enzyme deficiency.

Q: Are there any specific dietary restrictions mentioned for Curacil?

Regulatory patient information advises that there are generally no specific dietary restrictions required while taking Curacil. Patients should continue their normal diet unless otherwise instructed by a healthcare professional overseeing their treatment.

Q: Do official documents mention the risk of vision changes with Curacil?

Yes, official documents note that adverse reactions such as visual disturbances or blurred vision may occur during treatment. The regulatory labels state that the occurrence of such vision changes may be a reason for the treatment to be temporarily or permanently withheld.

How should Curacil be stored and disposed of?

The storage and disposal of Curacil (Fluorouracil) are governed by strict regulatory rules due to its classification as a cytotoxic agent.

Storage/Handling Rule Requirement Source Classification
Temperature Store at controlled room temperature (20 C to 25 C); Do not freeze the injectable solution. FDA / SmPC
Protection Keep the container tightly closed and inspect the injection solution visually for particulate matter before use. FDA / MedlinePlus
Stability Limit Prepared or diluted IV solutions must be used within 4 hours when stored at room temperature. FDA/DailyMed
Child Safety Keep out of reach of children and pets; this is a mandatory regulatory requirement for all forms. FDA / MedlinePlus
Disposal Disposal of unused product and all contaminated materials must adhere to cytotoxic/hazardous waste protocols as mandated by local regulations; discharge into wastewater is forbidden. SmPC / Regulatory Documents

The official profile mandates these storage constraints and disposal requirements to ensure product stability, maintain sterility after container penetration, and enforce safety handling protocols appropriate for a potent antineoplastic agent.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Curacil found in:

A-Z Index: